C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Smokers and Nonsmokers of the Ludwigshafen Risk and Cardiovascular Health Study

2014 ◽  
pp. 15-23 ◽  
Author(s):  
M. E. Kleber ◽  
R. Siekmeier ◽  
G. Delgado ◽  
T. B. Grammer ◽  
B. R. Winkelmann ◽  
...  
Keyword(s):  
Phospholipase A2 ◽  
Cardiovascular Health ◽  
Health Study ◽  
Cardiovascular Health Study ◽  
C Reactive Protein ◽  
Reactive Protein

Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study)

2003 ◽  
Vol 92 (3) ◽  
pp. 305-308 ◽  
Author(s):  
Winfried März ◽  
Karl Winkler ◽  
Markus Nauck ◽  
Bernhard O. Böhm ◽  
Bernhard R. Winkelmann
Keyword(s):  
Interleukin 6 ◽  
Cardiovascular Health ◽  
Health Study ◽  
Cardiovascular Health Study ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Lipoprotein-Associated Phospholipase A2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study)

2007 ◽  
Vol 53 (8) ◽  
pp. 1440-1447 ◽  
Author(s):  
Karl Winkler ◽  
Michael M Hoffmann ◽  
Bernhard R Winkelmann ◽  
Isolde Friedrich ◽  
Günther Schäfer ◽  
...  
Keyword(s):  
Risk Factors ◽  
Phospholipase A2 ◽  
Cardiac Death ◽  
High Sensitivity ◽  
Health Study ◽  
Cardiovascular Health Study ◽  
Cardiac Mortality ◽  
C Reactive Protein ◽  
Adjusted Risk ◽  
Reactive Protein

Abstract Background: Lipoprotein-associated phospholipase A2 (LpPLA2), also denoted as platelet-activating factor acetylhydrolase, is a lipoprotein-bound enzyme involved in inflammation and atherosclerosis. In this cohort study we investigated LpPLA2 activity to predict cardiac mortality in patients scheduled for coronary angiography. Methods: LpPLA2 activity was determined in 2513 patients with and in 719 patients without angiographically confirmed coronary artery disease (CAD). Results: During the median observation period of 5.5 years, 501 patients died. In patients with tertiles of LpPLA2 activity of 420–509 U/L or ≥510 U/L, unadjusted hazard ratios (HRs) for cardiac death were 1.7 (95% CI 1.3–2.4; P = 0.001), and 1.9 (95% CI 1.4–2.5; P <0.001), respectively, compared with patients with LpPLA2 activity ≤419 U/L. After we accounted for established risk factors and included angiographic CAD status, high-sensitivity C-reactive protein (hsCRP), and N-terminal pro-B-type natriuretic peptide, the 3rd tertile of LpPLA2 activity predicted cardiac 5-year mortality with an HR of 2.0 (95% CI 1.4–3.1; P = 0.001). LpPLA2 activity increased the adjusted risk for cardiac death by 2-fold in patients with hsCRP <3 mg/L in the 2nd (HR 2.4, 95% CI 1.4–4.2; P = 0.002) and 3rd (HR 2.1, 95% CI 1.1–4.0; P = 0.02) tertiles of LpPLA2 activity and in patients with hsCRP of 3–10 mg/L in the 3rd tertile (HR 1.9, 95% CI 1.0–3.6; P = 0.03) of LpPLA2 activity. Conclusions: LpPLA2 activity predicts risk for 5-year cardiac mortality independently from established risk factors and indicates risk for cardiac death in patients with low and medium-high hsCRP concentrations. Therefore, LpPLA2 activity may provide information for the identification and management of patients at risk beyond established risk stratification strategies.

Sign in / Sign up

Export Citation Format

Share Document